Theratechnologies (TH.TO,THTX) announced the FDA has approved the company's Prior Approval Supplement to the supplemental biologics license application for EGRIFTA SV, or tesamorelin for injection. Tesamorelin for injection is the only treatment approved in the U.S. to reduce excess abdominal fat in adults with HIV and lipodystrophy. Approval of the PAS removes any regulatory requirement for discretionary product release, thereby allowing the company to resume regular distribution of EGRIFTA SV.
"Securing FDA approval of the Prior Approval Supplement for the EGRIFTA SV sBLA closes a chapter of supply uncertainty and we are pleased to return to normal supply conditions," said Paul Lvesque, President and CEO of Theratechnologies.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.